- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. Motzer, R.J., Hutson, T.E., Olsen, M.R., Hudes, G.R., Burke, J.M., Edenfield, W.J., Wilding, G., Agarwal, N., Thompson, J.A., Cella, D., Bello, A., Korytowsky, B., Yuan, J., Valota, O., Martell, B., Hariharan, S., Figlin, R.A. J. Clin. Oncol. (2012)